Consortia
Join research groups that have come together in common cause.
Consortia
| Organization | Name | Description | Location | |
|---|---|---|---|---|
| The Coalition for Epidemic Preparedness Innovations | The Coalition for Epidemic Preparedness Innovations (Cepi) | New vaccines for a safer world | Multi-National | More Info |
| Arizona COVID-19 Genomics Union (ACGU) | Arizona COVID-19 Genomics Union to Track Coronavirus | Sequencing the SARS-CoV-2 genome | Arizona, United States | More Info |
| Massachusetts Consortion on Pathogen Readiness (MassCPR) | Massachusetts Consortion on Pathogen Readiness | Conducting research to address the current Covid-19 pandemic | Massachusetts, United States | More Info |
| Global Virus Network | Global Virus Network (GVN) | GVN's mission is to strengthen research related to the global pandemic | Multi-national | More Info |
| Coronavirus Treatment Acceleration Program (CTAP) | Coronavirus Treatment Acceleration Program (CTAP) | Special FDA program for approval of Covid-19 treatments | More Info | |
| National Institute of Health (NIH) | NIH to launch public-private partnership | Health agencies, leading pharmaceutical companies to join forces to accelerate pandemic response. | More Info | |
| California Life Sciences Association (CLSA) | California Life Sciences Association (CLSA) | Coronavirus (COVID-19) Resource Center | More Info | |
| BIO | Biotechnology Innovation Organization | BIO creates Covid-19 Hub to connect companies with capacity and resources with those that need them | More Info | |
| High Performance Computing Consortium | Covid-19 HPC Consortium | The COVID-19 High Performance Computing (HPC) Consortium members manage a range of computing capabilities that span from small clusters to some of the largest supercomputers in the world. | More Info | |
| C3.ai Digital Transformation Insitute | C3.ai Digital Transformation Institute | C3.ai DTI’s mission is to attract the world’s leading scientists to join in a coordinated and innovative effort to advance the digital transformation of business, government, and society | More Info | |
| EndPandemic National Data Consortium | endPandemic National Data Consortium | The EndPandemic National Data Consortium is here to help the medical community accelerate the discovery and implementation of effective treatments and vaccines against COVID-19. | More Info | |
| Johns Hopkins | Johns Hopkins Coronavirus Resource Center | Johns Hopkins experts in global public health, infectious disease, and emergency preparedness have been at the forefront of the international response to COVID-19. | More Info | |
| National Institute of Allergy and Infectious Disease (NIAID) | Infectious Diseases Clinical Research Consortium | To organize and conduct Phase 1 through 4 vaccine and treatment trials, including clinical studies in collaboration with industry partners | More Info | |
| Evaluate | Free COVID-19 Virtual Partnering Event | In the fight against the COVID-19 pandemic, the biopharma industry needs new ways to collaborate to bring treatments to patients faster. The answer? #PartneringAgainstCOVID19 From 20 April to 6 May 2020, this free, virtual partnering event gathers organizations with solutions for COVID-19 testing, treatment and prevention for online one-to-one partnering meetings. This initiative is backed by a consortium of biotech clusters and trade associations and represents a safe, structured and easy-to-use online meeting space for those working on solutions for COVID-19. | More Info | |
| Excelra | COVID-19 Drug Repurposing Database | Excelra’s COVID-19 Drug Repurposing Database has been assiduously compiled by our expert scientific teams in support of the urgent global need to identify safe and effective therapeutic options to treat the rampant novel coronavirus disease. This open-access database is a synoptic compilation of ‘Approved’ small molecules and biologics, which can rapidly enter either Phase 2 or 3, or may even be used directly in clinical settings against COVID-19. The database additionally includes information on promising drug candidates that are in various ‘clinical, pre-clinical and experimental’ stages of drug discovery and development. Supported with referenced literature, we provide mechanistic insights into SARS-CoV-2 biology and disease pathogenesis. We hope that these drug repositioning approaches can help the global biotech and pharma community develop treatments to combat COVID-19. | More Info | |
| Global Initiative on Sharing All Influenza Data (GISAID) | Global Initiative on Sharing All Influenza Data (GISAID) | Since the start of the COVID-19 outbreak and the identification of the pandemic virus, laboratories around the world are generating viral genome sequence data with unprecedented speed, enabling real-time progress in the understanding of the new disease and in the research and development of candidate medical countermeasures. Sequence data are essential to design and evaluate diagnostic tests, to track and trace the ongoing outbreak, and to identify potential intervention options | , | More Info |
| Covid- 19 Hg | Covid-19 Host Genetics initiative | The COVID-19 pandemic is a global crisis creating severe disruptions across the economy and health system. Insights into how to better understand and treat COVID-19 are desperately needed. Given the importance and urgency in obtaining these insights, it is critical for the scientific community to come together around this shared purpose. The COVID-19 host genetics initiative brings together the human genetics community to generate, share, and analyze data to learn the genetic determinants of COVID-19 susceptibility, severity, and outcomes. Such discoveries could help to generate hypotheses for drug repurposing, identify individuals at unusually high or low risk, and contribute to global knowledge of the biology of SARS-CoV-2 infection and disease. | , | More Info |